Clinical trials: Cardiotoxicity
Cancer
Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial
The purpose of this study is to examine adherence to cardio-oncology consultation.
- Trial name
- CARMA (NCT05403736)
- Testing
- Cardiac Aggressive Risk MitigAtion Plan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Colorectal Cancer
Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine
observational prospective study, designed for patients with colorectal cancer receiving for the first time 5-FU or capecitabine, with or without other chemotherapy combinations.
- Trial name
- NCT02665312
- Where
- 8 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Cardiac Toxicity, Cancer
Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies
The goal of this observational study is to evaluate the cardiovascular health and prognosis of adult patients with cancer, treated with cardiotoxic therapies.
- Trial name
- CV_CANCER (NCT06664528)
- Testing
- ECHOCARDIOGRAPHY, ELECTROCARDIOGRAPHY (ECG), LABORATORY TESTS
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Insufficiency;Cardiac, Cancer
Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment
New therapies for cancer increased patient survival, but led to the recognition of adverse effects associated with cancer treatment, such as the use of chemotherapy.
- Conditions
- Insufficiency;Cardiac, Cancer, Cardiotoxicity, Heart Failure
- Trial name
- NCT04047901
- Testing
- exercise training
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo General Hospital
Cardiac Toxicity, Lymphoma
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002827
- Testing
- bleomycin sulfate, filgrastim, dexrazoxane hydrochloride
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 294 people
- Sponsor
- Children's Oncology Group
HER2-positive Breast Cancer, HER2+ Breast Cancer
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Ten to 15% of patients with breast cancer are HER2 positive, with treatment focused on targeting the HER2 receptor. Although these treatments are generally well tolerated, they are associated with an increased risk of…
- Trial name
- NCT06844669
- Testing
- Carvedilol, Empagliflozin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Lymphoma, Large B-Cell, Diffuse
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised.
- Conditions
- Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity, Left Ventricular Dysfunction
- Trial name
- CONTROL (NCT05728632)
- Testing
- Nebivolol
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Giulio Stefanini
Breast Neoplasms, Cardiac Event
Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer
Totally 60 subjects will be included in the study. The present study was aimed to observe and evaluate the effect of Xinmailong injection on reducing cardiovascular toxicity associated with adjuvant chemotherapy after breast…
- Conditions
- Breast Neoplasms, Cardiac Event, Chemotherapeutic Toxicity
- Trial name
- NCT03785704
- Testing
- Xinmailong Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College
Malaria, Falciparum
Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam
This study is a multi-centre, open-label randomised trial to assess the efficacy, safety and tolerability of the Triple ACT artemether-lumefantrine+amodiaquine (AL+AQ) compared to the ACT artemether-lumefantrine (AL) in…
- Trial name
- TACT-CV (NCT03355664)
- Testing
- ACT, TACT
- Where
- 4 sites in Cambodia, Vietnam
- Volunteers
- 310 people
- Sponsor
- University of Oxford
Breast Cancer, Cardiotoxicity
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
This is an observational study for patients with breast cancer that will be treated with doxorubicin (Adriamycin) and/or trastuzumab (Herceptin).
- Conditions
- Breast Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
- Trial name
- CCT2 (NCT05078190)
- Testing
- Social Determinants of Health
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cardiovascular Complication, Cardiovascular Insufficiency
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer…
- Conditions
- Cardiovascular Complication, Cardiovascular Insufficiency, Cardiac Complication, Oncologic Complications
- Trial name
- NEOCARDIO (NCT03882580)
- Testing
- Anti-Cancer Agents
- Where
- 3 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Cardiotoxicity, Risk Factor, Cardiovascular
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with…
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer
- Trial name
- CCTGuide Pilot (NCT04023110)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, Stage I Breast Cancer
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Doxorubicin (Adriamycin), one of the drugs commonly used for the treatment of breast cancer, is in a class of medications called anthracyclines.
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT02096588
- Testing
- Simvastatin, Doxorubicin/cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Neoplasm, Breast
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020.
- Conditions
- Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents
- Trial name
- NCT05465031
- Testing
- Sacubitril-valsartan
- Where
- 4 sites in Poland
- Volunteers
- 600 people
- Sponsor
- Silesian Centre for Heart Diseases
Breast Cancer, Lymphoma
Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia
This is an observational study of the occurrence of cardiac toxicity in patients with breast cancer,lymphoma or leukemia receiving chemotherapy including an anthracycline.
- Conditions
- Breast Cancer, Lymphoma, Leukemia
- Trial name
- CarChem (NCT04541212)
- Testing
- Cardiac Imaging, Data Collection
- Where
- 6 sites in Canada
- Volunteers
- 169 people
- Sponsor
- Montreal Heart Institute
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy.
- Trial name
- NCT00003070
- Testing
- enalapril maleate, quality-of-life assessment
- Where
- 61 sites in United States, Canada and 1 more
- Volunteers
- 13 people
- Sponsor
- Children's Oncology Group
Breast Cancer, Cardiac Toxicity
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Breast Cancer, Cardiac Toxicity, Perioperative/Postoperative Complications
- Trial name
- NCT01093235
- Testing
- bevacizumab, cyclophosphamide, docetaxel
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Cancer, Immune-related Adverse Event
Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors
The goal of this prospective, multicentre study is to investigate short- and long-term cardiovascular effects in cancer patients treated with immune checkpoint inhibitors (ICIs).
- Conditions
- Cancer, Immune-related Adverse Event, Cardiac Abnormalities, Variable, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- CAVACI (NCT05699915)
- Testing
- Cardiology consultation, Chest Computed Tomography (CT) without contrast, Non-invasive endothelial function tests
- Where
- 4 sites in Belgium
- Volunteers
- 105 people
- Sponsor
- Algemeen Ziekenhuis Maria Middelares
Locally Advanced Lung Non-Small Cell Carcinoma
Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)
The prospective study LOCATION MATTERS aims to investigate the radiation-induced damage to the heart and the cardiovascular system in patients treated with thoracic radiotherapy.
- Trial name
- LM (NCT06361784)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine